RESUMO
BACKGROUND: There is insufficient systematized evidence on the effectiveness of individual intranasal medications in allergic rhinitis (AR). OBJECTIVES: We sought to perform a systematic review to compare the efficacy of individual intranasal corticosteroids and antihistamines against placebo in improving the nasal and ocular symptoms and the rhinoconjunctivitis-related quality of life of patients with perennial or seasonal AR. METHODS: The investigators searched 4 electronic bibliographic databases and 3 clinical trials databases for randomized controlled trials (1) assessing adult patients with seasonal or perennial AR and (2) comparing the use of intranasal corticosteroids or antihistamines versus placebo. Assessed outcomes included the Total Nasal Symptom Score, the Total Ocular Symptom Score, and the Rhinoconjunctivitis Quality-of-Life Questionnaire. The investigators performed random-effects meta-analyses of mean differences for each medication and outcome. The investigators assessed evidence certainty using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach. RESULTS: This review included 151 primary studies, most of which assessed patients with seasonal AR and displayed unclear or high risk of bias. Both in perennial and seasonal AR, most assessed treatments were more effective than placebo. In seasonal AR, azelastine-fluticasone, fluticasone furoate, and fluticasone propionate were the medications with the highest probability of resulting in moderate or large improvements in the Total Nasal Symptom Score and Rhinoconjunctivitis Quality-of-Life Questionnaire. Azelastine-fluticasone displayed the highest probability of resulting in moderate or large improvements of Total Ocular Symptom Score. Overall, evidence certainty was considered "high" in 6 of 46 analyses, "moderate" in 23 of 46 analyses, and "low"/"very low" in 17 of 46 analyses. CONCLUSIONS: Most intranasal medications are effective in improving rhinitis symptoms and quality of life. However, there are relevant differences in the associated evidence certainty.
Assuntos
Administração Intranasal , Corticosteroides , Antagonistas dos Receptores Histamínicos , Qualidade de Vida , Rinite Alérgica , Humanos , Antagonistas dos Receptores Histamínicos/uso terapêutico , Antagonistas dos Receptores Histamínicos/administração & dosagem , Corticosteroides/uso terapêutico , Corticosteroides/administração & dosagem , Rinite Alérgica/tratamento farmacológico , Rinite Alérgica Sazonal/tratamento farmacológico , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento , Antialérgicos/uso terapêutico , Antialérgicos/administração & dosagem , Rinite Alérgica Perene/tratamento farmacológicoRESUMO
INTRODUCTION: Allergic rhinitis (AR) is increasingly prevalent in India, affecting a significant portion of the population and adversely impacting their quality of life. This nationwide survey aimed to explore the perceptions and clinical preferences of Indian physicians regarding the perceived prevalence, common symptoms, and various available treatments for AR. METHODS: This cross-sectional, observational, digital questionnaire-based survey was conducted from September 2022 to March 2023, involving physicians sharing insights on prevalence rates, diagnostic approaches, medication preferences, and immunotherapy practices in AR management. RESULTS: A total of 1608 physicians participated in this survey. The majority of physicians (n=684, 42.5%) reported that the prevalence of AR in routine clinical practice is between 21 and 40%. Physicians also noted a substantial burden of AR with asthma (n=626, around 40%). Total IgE count was reported as a mandatory test for the diagnosis of AR by 47.5% of physicians (n=764). For the management of mild cases of seasonal or perennial AR, 980 (60.9%) physicians preferred fexofenadine as an oral antihistamine of choice. Fluticasone furoate was the preferred intranasal corticosteroid (INCS) option (67.1% of physicians (n=1079)), for the management of patients with moderate to severe AR, the most recommended duration of INCS therapy was two to four months (40.9% of physicians). Doctors recommended a montelukast and antihistamine combination in mild AR (n=152, 9.5%), mild AR not responding to antihistamine alone (n=291, 18.1%), moderate to severe AR along with INCS (n=252, 15.7%), and AR with mild asthma (n=74, 4.6%). The majority of physicians (n=1512, 75.6%) preferred using fexofenadine in combination with montelukast for the management of AR. The majority of physicians (n=839, 52.2%) opined that the efficacy rate of oral montelukast-fexofenadine was 60-90% in the management of mild-moderate AR. Around 55.3% of physicians (n=889) had not used immunotherapy in their clinical practice. CONCLUSION: These observations offer a holistic view of how Indian physicians perceive the management of AR, a condition highly prevalent in India and often associated with asthma. It also highlights the treatment strategies employed in their day-to-day clinical practice.
RESUMO
Adherence to treatment is essential in chronic rhinosinusitis with nasal polyposis (CRSwNP). Intranasal corticosteroids (INCS) are the first-line therapy, followed by systemic corticosteroids and surgery if needed. In cases of refractory disease, biologics are added to conventional treatment, making adherence to INCS crucial in assessing eligibility for these targeted therapies. The purpose of this review is to examine INCS adherence assessment and rate, before starting and during biologic therapy. We conducted a comprehensive literature review focusing on INCS adherence in CRSwNP treated with biologics, including randomized controlled trials and real-life studies. The search extended to studies on allergic and non-allergic rhinitis to provide broader insights into tools to assess the INCS adherence. The result was that adherence to INCS in CRSwNP is underexplored, with only a few studies addressing it directly. Various tools for adherence assessment have been identified, but none are universally accepted as standard. The review also highlights the complexity of factors influencing adherence rates. Effective CRSwNP management requires a paradigm shift to prioritize adherence in treatment guidelines and clinical practice. The review advocates for improved adherence assessment tools, a deeper understanding of influencing factors, and the integration of personalized medicine approaches, especially for biologic therapies.
RESUMO
Chronic rhinosinusitis ï¼CRSï¼ is a common chronic inflammatory disease in otorhinolaryngology, in which eosinophilic chronic rhinosinusitis with nasal polyps represents the difficult-to-treat chronic rhinosinusitis ï¼DTCRSï¼ with poor prognosis. DTCRS has a poor prognosis, which seriously affects people's physical and mental health, and is treated with various means, including medication, biotherapy and surgery. In recent years, endoscopic sinus surgery and postoperative local administration of nasal hormones as one of its treatment methods have achieved good results. In this paper, we review the relevant literature at home and abroad and give an overview for the treatment means of surgery, focusing on the effect of endoscopic sinus surgery on the distributable range of postoperative nasal glucocorticosteroids in patients with DTCRS, and then on the postoperative efficacy of the treatment, with a view to providing a reference for the clinical treatment of DTCRS.
Assuntos
Pólipos Nasais , Seios Paranasais , Rinite , Sinusite , Humanos , Rinite/terapia , Seios Paranasais/cirurgia , Sinusite/terapia , Corticosteroides/uso terapêutico , Pólipos Nasais/cirurgia , Doença CrônicaRESUMO
Allergic rhinitis is a common ailment in primary and acute care settings. Diagnosis is clinical, by means of history and physical examination. Referral to an allergist is considered when symptoms are difficult to manage and/or confirmation by means of further testing is desired. Management of allergic rhinitis should not be considered trivial, as multiple secondary effects can present as the course progresses. Several treatment modalities exist but should begin with glucocorticoid nasal sprays and systemic second- or third-generation antihistamines.
Assuntos
Rinite Alérgica , Humanos , Glucocorticoides/uso terapêutico , Glucocorticoides/administração & dosagem , Antagonistas dos Receptores Histamínicos/uso terapêutico , Rinite Alérgica/diagnóstico , Rinite Alérgica/terapia , Rinite Alérgica/tratamento farmacológicoRESUMO
Abstract Introduction In the current era, the major indication for septoplasty is nasal obstruction due to deviated nasal septum (DNS). Even though septoplasty is a commonly performed surgery, its effectiveness in relieving nasal obstruction in DNS has not been proven. Objective The present study involved the measurement of both objective (nasal patency) and subjective (quality of life measures) outcome measures for the evaluation of the efficacy of septoplasty as compared with medical management. Methods Patients with DNS presenting with nasal obstruction were included and randomized into a septoplasty group or into a nonsurgical management group, with 70 patients in each group. The improvement in nasal obstruction was assessed subjectively by the visual analogue scale (VAS), and the sino-nasal outcome test-22 (SNOT-22) and the nasal obstruction symptom evaluation (NOSE) questionnaires and was measured objectively by assessment of nasal patency by peak nasal inspiratory flow (PNIF) at 0, 1, 3, and 6 months of treatment in both groups. Results The average VAS, SNOT-22 and NOSE scores for the septoplasty versus the nonsurgical group before treatment were 6.28 versus 6.0, 19.5 versus 15, and 14 versus 12, respectively, and at 6 months post-treatment, the scores were 2.9 versus 5.26, 10 versus 12, and 8 versus 10 (p= 0.001), respectively. The average PNIF scores at 0 and 6 months were 60/50 l/min and 70/60 l/min, respectively, in the septoplasty group (p= 0.001); the scores at 0 and 6 months in the nonsurgical management group were 60/60 l/min and 70/70 l/min, respectively (p= 0.001). Conclusion Surgical correction of DNS by septoplasty improves nasal obstruction better than nonsurgical management at 6 months postsurgery.
RESUMO
Abstract Introduction: The adherence to medical treatment in allergic rhinitis is poorly evaluated in clinical practice. Objectives: To evaluate adherence to intranasal corticosteroids in the treatment of allergic rhinitis patients. Methods: This prospective study was conducted on adult patients who were admitted to the outpatient clinic of the otolaryngology department tertiary hospital. Patients diagnosed with moderate to severe persistent AR and who had not used any nasal sprays were enrolled in the study. The patients were provided with mometasone furoate nasal sprays. On the 30th day, all participants filled out a questionnaire regarding the factors that may have influenced their adherence to the treatment. Afterwards, each patient filled out the Turkish-language-validated Morisky Medical Adherence Scale (MMAS-8) form. Each factor that may have affected adherence to the prescribed medication was evaluated according to the MMAS-8 score and all variables were analyzed statistically. Results: Fifty-nine adult patients with a mean age of 32.5 years (range 21-52 years) were included in the study. The mean overall MMAS-8 score was 3.64. Two factors were significantly related to low adherence: number of dependent children (p = 0.001) and benefit from the medication (p = 0.001). In addition, patients with higher education levels seemed to be more adherent than the rest of the group. Conclusion: Clinicians must keep in mind the factors related to non-adherence in order to achieve better treatment outcomes. Therefore, based on our results, patients must be informed that medications should be taken properly regardless of the benefit, and the treatment should be scheduled with respect to daily activities, particularly for patients caring for more than two children.
Resumo Introdução: A adesão ao tratamento clínico de rinite alérgica é mal avaliada na prática clínica. Objetivos: Avaliar a adesão aos corticosteroides intranasais no tratamento de pacientes com rinite alérgica. Método: Este estudo prospectivo foi realizado com pacientes adultos admitidos no ambulatório do setor de otorrinolaringologia de um hospital terciário. Os pacientes diagnosticados com rinite alérgica moderada a persistente grave que não haviam ainda usado spray nasal foram incluídos no estudo. Os pacientes receberam sprays nasais de furoato de mometasona. No 30° dia, todos preencheram um questionário sobre os fatores que podem ter influenciado a sua adesão ao tratamento. Depois disso, cada paciente preencheu o formulário da Escala de Adesão Clínica Morisky validado para a língua turca (MMAS-8). Cada fator que pode ter afetado a adesão à medicação prescrita foi avaliado de acordo com o escore de MMAS-8 e todas as variáveis foram analisadas estatisticamente. Resultados: Foram incluídos no estudo 59 pacientes adultos com média de 32,5 anos (variação de 21-52). O escore total médio de MMAS-8 foi de 3,64. Dois fatores foram significantemente relacionados com a baixa adesão: número de dependentes infantis (p = 0,001) e benefício da medicação (p = 0,001). Além disso, os pacientes com níveis de ensino mais elevados pareceram ser mais adesistas do que o restante do grupo. Conclusão: Os médicos devem estar cientes dos fatores relacionados à falta de adesão, a fim de alcançar melhores resultados do tratamento. Portanto, com base em nossos resultados, os pacientes devem ser informados de que os medicamentos devem ser usados adequadamente independentemente do benefício, e o tratamento deve ser programado com relação às atividades diárias, especialmente para os pacientes que cuidam de mais de dois filhos.
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Adulto Jovem , Corticosteroides/uso terapêutico , Adesão à Medicação , Rinite Alérgica/tratamento farmacológico , Fatores Socioeconômicos , Administração Intranasal , Estudos Prospectivos , Inquéritos e Questionários , Resultado do Tratamento , Sprays Nasais , Centros de Atenção TerciáriaRESUMO
Objetivo: Revisar a literatura sobre prevalência, gravidade e fatores de risco para sibilância e asma em lactentes. Fontes de dados: Artigos originais, revisões e consensos indexados nos bancos de dados PubMed, MEDLINE, LILACS, SCIELO e publicações on tine, nos últimos 20 anos.Resultados: Neste trabalho são apresentadas pesquisas sobre a epidemiologia da sibilância e da asma nos primeiros anos de vida, as quais utilizaram diferentes métodos para definição de sibilância na infância e identificação dos seus fatores de risco. No entanto, a interação de fatores genéticos e ambientais foi unanimemente apontada como condição necessária para o desenvolvimento de sibilância e asma na infância. A maioria dos estudos encontrados foram realizados em países desenvolvidos Comentários: O conhecimento da prevalência, da gravidade e dos fatores de risco para sibilância e asma em lactentes é de grande interesse da comunidade médica do mundo todo. O aprofundamento de pesquisas sobre o tema é necessário para esclarecer as diferenças epidemiológicas e facilitar a implantação de medidas preventivas, o diagnóstico precoce da asma e seu tratamento mais adequado.
Objective: To review the literature on the prevalence, severity and risk factors for asthma and wheezing in infants.Sources: Original articles, reviews and consensus indexed in PubMed, MEDLINE, LILACS and SCIELO databases and online publications in the last 20 years. Results: This paper presents epidemiologic studles on asthma and wheezing in infants, which used different criteria to define childhood wheezing and identify their risk factors. However, these researches pointed the interaction of genetic and environmental factors as a condttlon for the development of wheezing and childhood asthma, without exception. Most studies were conducted in affluent countries. Comments: Knowledge of the prevalence, severity and risk factors for wheezing and asthma in infants is of great interest in the medicai community worldwide. More research on the subject are required to clarify the epidemiological differences and favor the establishment of preventive actions, early diagnosis of asthma and opportune treatment for this condition.
Assuntos
Humanos , Lactente , Asma , Suscetibilidade a Doenças , Lactente , Comportamento do Lactente , Pneumopatias , Sons Respiratórios , Técnicas e Procedimentos Diagnósticos , Epidemiologia , Métodos , Prevalência , MétodosRESUMO
Objetivo: Revisar as características farmacológicas dos corticosteroides tópicos nasais (CI) e suas implicações clínicas e terapêuticas.Método: Revisão da literatura sobre os CI disponíveis comercialmente, como: acetonido de triancinolona, budesonida, dipropionato de beclometasona, ciclesonida, propionato de f1uticasona, furoato de mometasona e furoato de f1uticasona. Foram avaliados dados sobre indicações, formulações, farmacocinética, eventos adversos, comparação com outros tratamentos, eficácia em sintomas nasais e extra-nasais, qualidade de vida e o uso na população pediátrica. Resultados: CI são eficazes no tratamento da rinite alérgica, rinossinusite e pólipos nasais. Os ésteres propionato e o furoato são mais Iipofílicos e com maior absorção na mucosa nasal. CI são auxiliares no controle da asma e na melhora da qualidade de vida. O furoato de rnornetasona, furoato de f1uticasona, acetonido de triancinolona e a ciclesonida podem ser utilizados em crianças a partir de dois anos de idade. Conclusões: CI é a classe farmacológica mais efetiva para o tratamento da rinite alérgica, com, bom perfil de segurança, inclusive na população pediátrica.
To review pharmacologic profile, clinicai and therapeutic implications of topical intranasal corticosteroids (CI).Methods: The available literature was searched on CI such as triamcinolone acetonide, budesonide, beclomethasone dipropionate, clclesoníde, f1uticasone propionate, mometasone furoate and f1uticasone furoate. Data on clinicai indications, formulations, pharmacokinetic, adverse events, comparison with other drugs, nasal and extra-nasal symptoms efficacy, quality of Iife and pediatric use were díscussed.Results: Intranasal corticosteroids are effective treatment for allergic rhinttís, rhinosinusitis and nasal polyposis. The ester propionate and furoato are more lipophilic with better absorption on nasal mucosa. Additionally, CI may help to control asthma and improve quality of life. Mometasone furoato, f1uticasona furoate, triancinolone acetonide and ciclesonide can be used in children older than 2 years.Conclusions: Intranasal corticosteroids are the most effective drugs to treat allergic rhinitis and have a good safety profile, including for pediatric population.